Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Perez on the Antibody-Drug Conjugate T-DM1

February 13th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

Dr. Tripathy on 10 Versus 5 Years of Adjuvant Tamoxifen

February 12th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the ATLAS trial that compared 5 years of adjuvant tamoxifen to 10 in patients with estrogen receptor-positive early breast cancer.

A Journey of a Lifetime: Noted Breast Cancer Researcher in Far-Flung Pursuit of a "Cure"

February 12th 2013

Leyland-Jones, MB BS, PhD, a renowned oncologist and translational scientist, has helped develop several mainstay oncologic treatments and the targeted breast cancer therapy trastuzumab.

Dr. William Gradishar Reviews the Eribulin 301 Study

February 8th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes results from the 301 Study that compared eribulin mesylate to capecitabine for locally advanced or metastatic breast cancer.

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

February 7th 2013

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

SABCS Report: Tackling the Optimal Use of Established Therapies

February 6th 2013

In interviews with OncologyLive, Debu Tripathy, MD, and William Gradishar, MD, discussed their views of the most important abstracts presented during the San Antonio Breast Cancer Symposium.

Dr. Mamounas on Surgery in Stage IV Breast Cancer

February 6th 2013

Eleftherios (Terry) P. Mamounas, MD, MPH, from the Aultman Hospital Cancer Center, discusses the controversial topic of surgery for patients who present with stage IV breast cancer at the time of diagnosis.

HER2 Mutations Identified as Treatment Targets in Patients With HER2-Negative Breast Cancer

February 5th 2013

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

Dr. Debu Tripathy Reviews the Phase III CONFIRM Trial

February 4th 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the final analysis of overall survival for the phase III CONFIRM trial.

Expert Analysis From SABCS 2012: An Interview With Edith Perez, MD

February 1st 2013

Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.

Guideline Adherence Is Vital to HER2 Accuracy

January 31st 2013

Efforts to improve guidelines continue for HER2 testing and the evaluation of whether patients' tumors are estrogen receptor-positive and progesterone receptor-positive.

Breast-Conserving Treatment of Breast Cancer

January 29th 2013

An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.

Dr. Perez on the Adjuvant Treatment of Breast Cancer

January 28th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, reviews clinical trials that are investigating the optimal adjuvant treatment for patients with breast cancer.

Addition of PI3K Inhibitor May Prevent or Delay Resistance to Therapy in HER2+ Breast Cancer

January 23rd 2013

A new study found that patients with HER2-positive breast cancer who are receiving anti-HER2 therapy could prevent or delay resistance when a phosphatidylinositol-3 kinase (PI3K) inhibitor is added during treatment.

The Future of BRCA1/BRCA2 Testing

January 22nd 2013

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Dr. Gradishar Reviews Findings From the LEA Trial

January 17th 2013

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, reviews results from the phase III LEA trial that investigated add-on bevacizumab in breast cancer.

Dr. Sara Tolaney on Cabozantinib in Breast Cancer

January 16th 2013

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Dr. Schuster on Detecting Bone Metastases in Breast Cancer

January 15th 2013

David Schuster, MD, director, from Emory University, compares the efficacy of bone scans and FDG-PET/CT scans for detecting bone metastases in patients with breast cancer.

Dr. Debu Tripathy on the CDK4/6 Inhibitor PD 0332991

January 11th 2013

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses a phase II trial that examined the CDK inhibitor PD 0332991 for women with advanced estrogen receptor-positive breast cancer.

Dr. Perez on the Phase III Eribulin/Capecitabine Study

January 9th 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, Florida, discusses the results of a phase III study comparing the efficacy of eribulin mesylate to capecitabine in patients with locally advanced or metastatic breast cancer.